Perspectives on the future of pegfilgrastim biosimilars

Category: Meeting Report
Author(s): , ,
Visits: 38 total, 1 today

Author byline as per print journal: Professor Pere Gascón, MD; Ruediger Jankowsky, PhD; Karsten Roth, PhD

Abstract: Cinfa Biotech, the biosimilars company of the Cinfa Group, held an international webcast to discuss pegfilgrastim and the prospective pegfilgrastim biosimilar approaches to treat chemotherapy-induced neutropenia. Professor Dr Pere Gascón delivered a talk on perspectives of pegfilgrastim. The webinar finalized with a talk on the B12019 clinical development programme by Dr Karsten Roth and a well-supported conclusion by Dr Ruediger Jankowsky that biosimilars are a necessity for supportive care in oncology. Webinar participants were made up of industry decision-makers, clinical research specialists and expert members of the international biosimilar community, such as analysts, practitioners and reporters.

Subscribe now to GaBI Journal to view full information of this article to be published in the next journal issue.

Go Back Print

Leave a Reply